Partners4Access (P4A), the specialists in orphan drug access, are launching a weekly newsletter focussing on key developments in the rare diseases and orphan drugs market access landscape.
The service will offer a comprehensive weekly summary of the most interesting and relevant news articles, beginning on Thursday 16th November 2017.
The newsletter will allow readers to stay updated with the latest news in one simple email format and will aim to cover the following topics:
- Rare diseases, gene and cell therapy – includes national and international rare disease funding and policy developments, clinical breakthroughs, and new initiatives from patient organisations
- Market access – includes regulatory changes, reimbursement and pricing decisions focusing on orphan diseases
- Movers and Shakers in the industry – includes top management changes in pharmaceutical companies and regulatory organisations
- Upcoming Events – includes key conferences and seminars related to market access and rare disease, and opportunities to meet members of the P4A team
Sophie Schmitz, Managing Partner at P4A said, “The world of rare disease and orphan drugs is a truly dynamic environment, with ongoing changes across new medical technologies, new funding measures and payer/HTA policies. This newsletter is designed to help stakeholders in the orphan drug world keep up to date on the latest trends and share some implications for industry.”
To subscribe and for more information about Partners4Access, please email us at firstname.lastname@example.org.
Partners4Access are global consultants specialised in orphan drug access. The company supports the biotechnology and pharmaceutical industry along their launch journey to help secure successful pricing, reimbursement and access for orphan drugs. Partners4Access has solid partnerships with clients supporting their strategy and operations to effectively ensure launch success.